# UCB Biopharma S.P.R.L. clinical trials: 48 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 48 trials with UCB Biopharma S.P.R.L. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by UCB Biopharma S.P.R.L.: 48 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ucb-biopharma-s-p-r-l

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 48
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 48, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 6, 2021 | NCT04875962 | A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's... | UCB Biopharma S.P.R.L. | Phase 1 | Completed | Parkinson's Disease | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04875962) |
| October 23, 2019 | NCT04136444 | A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function | UCB Biopharma S.P.R.L. | Phase 1 | Terminated | Healthy Study Participants, Impaired Hepatic Function | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04136444) |
| October 15, 2019 | NCT04126343 | A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants | UCB Biopharma S.P.R.L. | Phase 1 | Terminated | Healthy Study Participants | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04126343) |
| August 30, 2019 | NCT04075409 | A Study to Test the Safety, and Tolerability of Padsevonil in Healthy Male Japanese Study Participants | UCB Biopharma S.P.R.L. | Phase 1 | Completed | Healthy Japanese Participants | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04075409) |
| July 31, 2019 | NCT04039919 | A Study to Test the Pharmacodynamic, Pharmacokinetic, Safety, and Tolerability of Padsevonil in Healthy Study Participants Receiving Either... | UCB Biopharma S.P.R.L. | Phase 1 | Terminated | Healthy Participants | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04039919) |
| July 9, 2019 | NCT04013191 | A Study to Test the Safety and Tolerability of Single and Multiple Doses of Padsevonil in Adult and Elderly Study Participants | UCB Biopharma S.P.R.L. | Phase 1 | Completed | Elderly Study Participants, Adult Study Participants | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04013191) |
| March 29, 2019 | NCT03895385 | A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects | UCB Biopharma S.P.R.L. | Phase 1 | Completed | Healthy Volunteers | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03895385) |
| March 4, 2019 | NCT03861481 | A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating... | UCB Biopharma S.P.R.L. | Phase 2 | Completed | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03861481) |
| March 1, 2019 | NCT03859219 | A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy... | UCB Biopharma S.P.R.L. | Phase 1 | Completed | Healthy-volunteers | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03859219) |
| October 16, 2018 | NCT03707717 | A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult... | UCB Biopharma S.P.R.L. | Phase 1 | Completed | Healthy Volunteers | 189 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03707717) |
| October 3, 2018 | NCT03695094 | A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil | UCB Biopharma S.P.R.L. | Phase 1 | Completed | Epilepsy | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03695094) |
| September 26, 2018 | NCT03685630 | A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects... | UCB Biopharma S.P.R.L. | Phase 3 | Completed | Partial Seizures With or Without Secondary Generalization, Epilepsy | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03685630) |
| July 30, 2018 | NCT03605082 | A Study to Test the Safety and Tolerability and Pharmacokinetics of Single Doses of UCB0107 in Healthy Japanese Subjects | UCB Biopharma S.P.R.L. | Phase 1 | Completed | Healthy Japanese Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03605082) |
| June 18, 2018 | NCT03559673 | Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures | UCB Biopharma S.P.R.L. | Not applicable | No longer available | Epilepsies, Partial | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03559673) |
| March 29, 2018 | NCT03480243 | Study to Evaluate the Effect of Coadministered Erythromycin on the Pharmacokinetics and Safety of Padsevonil | UCB Biopharma S.P.R.L. | Phase 1 | Completed | Pharmacokinetics | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03480243) |
| March 13, 2018 | NCT03464227 | A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male Subjects | UCB Biopharma S.P.R.L. | Phase 1 | Completed | Healthy Male Volunteers | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03464227) |
| January 23, 2018 | NCT03405714 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects \>= 1 Month to \< 16 Years of Age... | UCB Biopharma S.P.R.L. | Phase 2 | Completed | Epilepsy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03405714) |
| December 14, 2017 | NCT03373383 | Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy | UCB Biopharma S.P.R.L. | Phase 2 | Completed | Drug-resistant Epilepsy, Focal-Onset Seizures | 411 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03373383) |
| November 30, 2017 | NCT03357471 | Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to... | UCB Biopharma S.P.R.L. | Phase 3 | Completed | Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03357471) |
| July 2, 2017 | NCT03204474 | A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male... | UCB Biopharma S.P.R.L. | Phase 1 | Completed | Healthy Male Chinese Volunteers | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03204474) |
| May 30, 2017 | NCT03168984 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects | UCB Biopharma S.P.R.L. | Phase 1 | Completed | Healthy Japanese and Caucasian Subjects | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03168984) |
| April 6, 2017 | NCT03103919 | Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management | UCB Biopharma S.P.R.L. | Phase 4 | Completed | Parkinson´s Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03103919) |
| March 22, 2017 | NCT03086382 | A Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects | UCB Biopharma S.P.R.L. | Phase 1 | Completed | Healthy Male Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03086382) |
| February 14, 2017 | NCT03052751 | Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis | UCB Biopharma S.P.R.L. | Phase 2 | Completed | Myasthenia Gravis | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03052751) |
| February 13, 2017 | NCT03051217 | A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis | UCB Biopharma S.P.R.L. | Phase 2/3 | Completed | Moderate to Severe Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis | 127 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03051217) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 21 |
| Phase 2 | 11 |
| Phase 2/3 | 1 |
| Phase 3 | 10 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 40 |
| Terminated | 7 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Epilepsy | 12 |
| Psoriasis | 5 |
| Seizures | 3 |
| Parkinson Disease | 3 |
| Lupus Erythematosus, Systemic | 2 |
| Spondylitis, Ankylosing | 2 |
| Lymphoma, Follicular | 1 |
| Myasthenia Gravis | 1 |
| Axial Spondyloarthritis | 1 |
| Non-Radiographic Axial Spondyloarthritis | 1 |
| Disease | 1 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 |
| Epilepsies, Partial | 1 |
| Arthritis, Psoriatic | 1 |
| Severe combined immunodeficiency with sensitivity to ionizing radiation | 1 |
| Spasms, Infantile | 1 |
| Spasm | 1 |
| Drug Resistant Epilepsy | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Inspection companies in the United States](https://specstream.ai/data/businesses/inspection-companies/united-states)
- [Mechanical engineering firms in the United States](https://specstream.ai/data/businesses/mechanical-engineering-firms/united-states)
- [Paralegal companies in the United States](https://specstream.ai/data/businesses/paralegal-companies/united-states)
- [Public utilities in the United States](https://specstream.ai/data/businesses/public-utilities/united-states)
- [Speech therapy clinics in the United States](https://specstream.ai/data/businesses/speech-therapy-clinics/united-states)
- [Urology practices in the United States](https://specstream.ai/data/businesses/urology-practices/united-states)
